ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Panitumumab

Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.

Drug pagePanitumumab: every studyAll 196 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 10, 200537 company-led studies, 2 open or runningNext primary completion: Sep 25, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen351 open or runningphase 3since Jun 10, 2005Apr 25, 2002Sep 25, 2028phase 3 · NCT06252649
Dr. Reddy's Laboratoriesits history only10 open or runningphase 4since Nov 24, 2014Nov 24, 2014none ahead
R-Pharmits history only11 open or runningphase 1since Apr 14, 2026Apr 14, 2026none ahead

Also a collaborator on its studies: Takeda and Immunex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Apr 25, 2002.

  1. Dec 12, 2006Phase 2 study in Colonic NeoplasmsNCT00411450 · 116 enrolled
  2. Jan 4, 20073 phase 2 studiesNCT00418938, NCT00425204, NCT00425035
  3. Mar 8, 20072 phase 2 studiesNCT00446446, NCT00454779
  4. Jul 12, 20072 phase 2 studiesNCT00500760, NCT00508404
  5. Oct 18, 2007Phase 2 study in NeoplasmsNCT00547157 · 152 enrolled
  6. Nov 21, 2007Phase 1 study in Colorectal NeoplasmsNCT00563316 · 28 enrolled · United States, Canada
  7. Jan 31, 2008Phase 2 study in Pancreatic NeoplasmsNCT00613730 · 3 enrolled
  8. Apr 10, 2008Phase 1 study in Solid TumorsNCT00658658 · 31 enrolled · United States
  9. Sep 18, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT00756444 · 67 enrolled
  10. Nov 6, 2008Phase 2 study in Colonic NeoplasmsNCT00819780 · 285 enrolled · United States, Belgium, Canada and more
  11. Oct 22, 2009Phase 3 study in Colorectal NeoplasmsNCT01001377 · 1,010 enrolled · United States, Australia, Belgium and more
  12. Mar 31, 2011Phase 3 study in Colorectal NeoplasmsNCT01412957 · 377 enrolled · Brazil, Canada, Chile and more
  13. Jan 6, 2022Phase 3 study in Colorectal NeoplasmsNCT05198934 · 160 enrolled · United States, Australia, France and more
  14. Jan 15, 2024Phase 3 study in Colorectal NeoplasmsNCT06252649 · 450 planned · United States, Argentina, Australia and more

Ahead

  1. Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT06252649

TargetBeta

EGFR →read by rule
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 35 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingSep 25, 2028450
NCT05198934Colorectal Neoplasms · United States, Australia, France and more3CompletedJul 16, 2025160
NCT01412957Colorectal Neoplasms · Brazil, Canada, Chile and more3CompletedJun 2014377
NCT01001377Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedFeb 5, 20131,010
NCT00819780Colonic Neoplasms · United States, Belgium, Canada and more2CompletedMay 30, 2012285
NCT00756444Squamous Cell Carcinoma of Head and Neck2CompletedMar 30, 201267
NCT00658658Solid Tumors · United States1CompletedMar 201531
NCT00613730Pancreatic Neoplasms2TerminatedApr 20093
NCT00563316Colorectal Neoplasms · United States, Canada1CompletedMar 200928
NCT00547157Neoplasms2CompletedDec 2011152
NCT00508404Colorectal Neoplasms2CompletedJun 1, 2009154
NCT00500760Head and Neck Neoplasms2CompletedMar 29, 2011153
NCT00454779Neoplasm Metastasis · United States, Austria, Belgium and more2CompletedJun 11, 2012113
NCT00446446Neoplasms2CompletedDec 15, 201052
NCT00425204Colorectal Neoplasms2CompletedSep 200731
NCT00425035Kidney Neoplasms2Completed115
NCT00418938Neoplasms2CompletedMay 10, 2012266
NCT00411450Colonic Neoplasms2CompletedJan 2009116
NCT00364013Colorectal Neoplasms3CompletedAug 1, 20091,183
NCT00339183Colorectal Neoplasms3CompletedApr 1, 20091,186
NCT00327119Colorectal Neoplasms2Completed50
NCT00352950Neoplasms1Withdrawn0
NCT00115765Colorectal Neoplasms3CompletedMay 31, 20071,053
NCT00113776Colorectal Neoplasms2Completed
NCT00113763Colorectal Neoplasms3CompletedOct 1, 2008463
NCT00111774Colorectal Neoplasms2Completed150
NCT00111761Colorectal Neoplasms2CompletedFeb 200843
NCT00101920Carcinoma, Non-Small-Cell Lung2CompletedDec 200450
NCT00101907Lung Neoplasms1TerminatedJun 200741
NCT00094835Lung Neoplasms2CompletedMar 200751
NCT00091806Neoplasms1CompletedApr 200686
NCT00089635Colorectal Neoplasms2CompletedJan 1, 2007203
NCT00083616Colorectal Neoplasms2CompletedMay 2007185
NCT00061126Prostatic Neoplasms · United States2Completed50
NCT00034346Carcinoma, Non-Small-Cell Lung2Completed194

How it is read

Names in the registry

  • “Panitumumab”, 29 entries
  • “ABX-EGF”, 5 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “Panitumumab (ABX-EGF)”, 2 entries
  • “RPH-030”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.